Pulmonary Embolism Clinical Trial
— VEREEFYOfficial title:
Validation of Epworth Richmond's Echocardiography Education Focused Year
Verified date | August 2017 |
Source | Epworth Healthcare |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The use of echocardiography in intensive care is a developing field. In expert hands
echocardiography has proven its utility in diagnosing cardiac pathology, differentiating
shock states and in haemodynamic monitoring. However, whether the results obtained by experts
can be generalized to trainees or specialists with limited training remains unclear. Further,
concerns around training time and cost for intensive care staff have been a factor in
limiting the uptake of echocardiography in intensive care.
The investigators aim to assess the diagnostic accuracy of Australian ICU doctors in training
after completion of the current minimum training. After completing a structured teaching
program and 30 mentored training scans trainees will be assessed on their accuracy with
echocardiography. In the research phase trainees will complete a further 40 scans with each
one matched with an expect scan. The results from the expert and trainee scans will be
compared to determine the trainee's accuracy.
Status | Completed |
Enrollment | 252 |
Est. completion date | May 1, 2017 |
Est. primary completion date | May 1, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Registrar Inclusion: - At least 12 month appointment in Epworth Richmond ICU - Completion of theoretical component of Epworth Richmond ICU echocardiography program - Completion of 30 echocardiography scans Registrar Exclusion: • Previous experience in echocardiography prior to commencing at Epworth Richmond. Patient Inclusion - Patient in ICU or CCU - 18 years or older - Not likely to be discharged before completion of the scan Patient Exclusion - Likely to be discharged within next two hours - Atrial fibrillation - Presence of subcostal or intercostal drains or pneumothorax - Unable to be consented - Treating intensivist deems inclusion in study not suitable. |
Country | Name | City | State |
---|---|---|---|
Australia | Epworth Richmond | Melbourne | Victoria |
Lead Sponsor | Collaborator |
---|---|
Epworth Healthcare | University of Melbourne |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Agreement between registrar and expert assessment of Left ventricular (LV) function | Four months | ||
Secondary | Comparison of expert and registrar quantitative measures of Left vwentricular Internal Diameter in Diastole (LVIDd) | Four months | ||
Secondary | Comparison of expert and registrar quantitative measures of Left Ventricular Outflow Tract (LVOT) diameter | Four months | ||
Secondary | Comparison of expert and registrar quantitative measures of Left Ventricular Outflow Tract Velocity Time Integral (LVOT VTI) | Four months | ||
Secondary | Comparison of expert and registrar quantitative measures of TR V max | Four months | ||
Secondary | Comparison of expert and registrar quantitative measures of Tricuspid annular Plane Systolic Excursion (TAPSE) | Four months | ||
Secondary | Comparison of expert and registrar quantitative measures of IVC diameter | Four months | ||
Secondary | Comparison of expert and registrar qualitative assessment of pericardial fluid | Four months | ||
Secondary | Comparison of expert and registrar qualitative assessment of Left Ventricle : Right Ventricle size ratio | Four months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05050617 -
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
|
||
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Completed |
NCT03915925 -
Short-term Clinical Deterioration After Acute Pulmonary Embolism
|
||
Completed |
NCT02502396 -
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT04454554 -
Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
|
||
Completed |
NCT03173066 -
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
|
Phase 1 | |
Terminated |
NCT03002467 -
Impact Analysis of Prognostic Stratification for Pulmonary Embolism
|
N/A | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT02611115 -
Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.
|
N/A | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT01326507 -
Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism
|
N/A | |
Completed |
NCT02476526 -
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00780767 -
Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism
|
Phase 2 | |
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT00244725 -
Odiparcil For The Prevention Of Venous Thromboembolism
|
Phase 2 |